YHC1102 / Yuhan Corp, Gilead - LARVOL DELTA

Yuhan Corporation Returns MASH Treatment Technology Exported 5 Years Ago… “Looking for New Partner” [Google translation] (Money Today) - "Yuhan Corporation announced on the 11th that it had received notice from Gilead Sciences that it was canceling and returning the global (excluding Korea) development rights for the MASH treatment candidate. The contract was to license out the exclusive rights to a new drug candidate that acts on two drug targets for MASH treatment to Gilead Sciences in 2019. The contract was worth up to $785 million (about 1 trillion won), including the down payment and stage-by-stage milestones based on development, approval, and sales."

Licensing / partnership • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis